Especially, CD8+ cytotoxic T lymphocytes (CTL) plays a central role in immunotherapy-induced tumor immunity and the infiltration of CD8+ CTL is positively correlated with the efficacy of ICB therapy [22, 23]. Here, CD8A is linked to neoplasm.